CLS: Notice of Extraordinary General Meeting at Clinical Laserthermia Systems

Right to participate and registration

Shareholders wishing to participate in the meeting must:

• Be registered in the shareholders' register maintained by Euroclear Sweden AB by Friday, October 11, 2024, and
• Notify the company no later than Tuesday, October 15, 2024, in writing to Clinical Laserthermia Systems AB, Medicon Village, Scheelegatan 2, 223 63 Lund. Notification can also be made by phone to +46 702 90 33 00 or by email to info@clinicallaser.se.The notification should include the shareholder's full name, personal or organization number, shareholding, address, daytime phone number, and, if applicable, details of proxies or assistants (a maximum of 2). The notification should also be accompanied, where applicable, by proxies, registration certificates, and other authorization documents.

Nominee-registered shares

Those who have had their shares nominee-registered must, to have the right to attend the Extraordinary General Meeting, have the shares registered in their own name through the nominee, so that they are registered in the share register held by Euroclear Sweden AB on the record date, Friday, October 11, 2024. Such registration may be temporary (so-called voting registration). Shareholders wishing to register the shares in their own name must, in accordance with the procedures of each nominee, request the nominee to make such voting registration. Voting registration requested by a shareholder in such time that the registration has been made by the relevant nominee no later than Tuesday, October 15, 2024, will be considered in the preparation of the share register.

Proxies, etc

If shareholders are to be represented by a proxy, the proxy must have a written, dated, and signed proxy from the shareholder to the Extraordinary General Meeting. The proxy must not be older than one year, unless a longer period of validity (but no more than five years) has been stated in the proxy. If the proxy has been issued by a legal entity, the proxy must also present the current registration certificate or equivalent authorization document for the legal entity. To facilitate admission, copies of the proxy and other authorization documents should be attached to the notification to the Extraordinary General Meeting. Proxy forms are available on the company's website www.clinicallaser.se and are sent by post to shareholders who contact the company and provide their address.

Number of shares and votes

The number of outstanding shares and votes in the company at the time of this notice is 13 931 707 shares, of which 3000 are A-shares (10 votes each) and 13 928 707 are B-shares (1 vote each). The number of votes at the time of this notice amounts to 13 958 707 votes. The company does not hold any own shares.

Proposed agenda:

1.    Election of the chairman.
2.    Preparation and approval of the voting list.
3.    Approval of the agenda.
4.    Election of one or two certifiers.
5.    Determination of whether the meeting has been duly convened.
6.    Election of the board of directors.
7.    Closing of the Extraordinary General Meeting.

Decision Proposal in Brief:

Election of the Board of Directors (item 6)

Shareholders have notified that they propose the re-election of Lars-Erik Eriksson, Marika Crohns, and Sandra Brandmeier as board members. Furthermore, shareholders propose the new election of Peter Mantas and Peter Max.

Hans von Celsing and Paolo Raffaelli have announced that they are not standing for re-election.

Personal data

Personal data obtained from the share register held by Euroclear Sweden AB, notification of attendance at the Extraordinary General Meeting, and information about proxies, representatives, agents, and assistants will be used for registration, preparation of the voting list for the Extraordinary General Meeting, and, where applicable, the minutes of the Extraordinary General Meeting.

Other information

Necessary documents, complete proposals for decisions, and proxy forms will be made available at the company's office at Medicon Village, Scheelegatan 2, 223 63 Lund, and on the company's website www.clinicallaser.se before the Extraordinary General Meeting and will be sent to shareholders who request it and provide their postal address.

Shareholders have the right to request information in accordance with Chapter 7, Section 32 of the Swedish Companies Act (2005:551). Requests for such information should be made in writing to Clinical Laserthermia Systems AB, Medicon Village, Scheelegatan 2, 223 63 Lund or by email to info@clinicallaser.se.Theinformation is provided by being made available at Clinical Laserthermia Systems AB, Medicon Village, Scheelegatan 2, 223 63 Lund and on info@clinicallaser.sewithinthe same time period. The information is also sent within the same time period to the shareholder who has requested it and provided their address.

Lund, September 2024

Clinical Laserthermia Systems AB

THE BOARD

About CLS

Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold directly or through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se